Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation
- 8 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 25 (6) , 1433-1440
Abstract
Background: A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects. To demonstrate long-term safety of ganirelix (GnRH antagonist) treatment in controlled ovarian stimulation (COS), follow-up data on pregnancy and neonatal outcome were analysed for 1000 fetuses (>= 16 gestational weeks). Methods: Obstetrical and neonatal data on 839 pregnancies, resulting in 969 live born infants after ganirelix treatment were compared with a historical cohort of 753 pregnancies after long GnRH agonist (buserelin) treatment, resulting in 963 live born infants. All treatment cycles were performed in a single fertility centre. The infants were examined at the Universitair Ziekenhuis Brussel using an identical follow-up protocol. Incidence of major malformations (i.e. causing functional impairment or requiring surgical correction) was the primary end-point and was analysed by logistic regression including treatment, age of mother, IVF method and pregnancy type (singleton/multiple) as independent variables. Results: There were no relevant differences in maternal characteristics, fertilization method and pregnancy and delivery complications between the ganirelix and historical GnRH agonist groups. There were relatively more multiple pregnancies in the historical GnRH agonist group (31.9%) than the ganirelix group (18.7%; P < 0.0001). The groups were comparable with respect to pregnancy loss after 16 weeks gestation. The incidence of major congenital malformations in fetuses with gestational age >= 26 weeks was 5.0% in the ganirelix cohort versus 5.4% in the historical GnRH agonist group (odds ratio 0.94, 95% confidence interval, 0.62-1.42). Conclusion: In terms of neonatal outcome and risk of major malformations, treatment with the GnRH antagonist ganirelix during COS is as safe as traditional GnRH agonists.Keywords
This publication has 19 references indexed in Scilit:
- Babies born after ART treatment cost more than non-ART babies: a cost analysis of inpatient birth-admission costs of singleton and multiple gestation pregnanciesHuman Reproduction, 2007
- Assisted reproductive technologies and the risk of birth defects—a systematic reviewHuman Reproduction, 2005
- A Meta-Analysis of Controlled Studies Comparing Major Malformation Rates in IVF and ICSI Infants with Naturally Conceived ChildrenJournal of Assisted Reproduction and Genetics, 2004
- Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysisInternational Journal of Epidemiology, 2004
- Maternal and Paternal Risk Factors for Cryptorchidism and Hypospadias: A Case–Control Study in Newborn BoysEnvironmental Health Perspectives, 2004
- Perinatal Outcomes in Singletons Following In Vitro Fertilization: A Meta-AnalysisObstetrics & Gynecology, 2004
- Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studiesBMJ, 2004
- Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation?Fertility and Sterility, 2000
- Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCGHuman Reproduction, 2000
- Deliveries and children born after in-vitro fertilisation in Sweden 1982–95: a retrospective cohort studyThe Lancet, 1999